Evaluating the effects of stopping opioids on esophageal dysfunction
Prospective Evaluation of the Effect of Opioid Cessation on Opioid-Induced Esophageal Dysfunction (OIED)
This study is testing how stopping opioid use affects people with esophageal problems caused by opioids to see if it helps improve their symptoms.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 26 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 1 site (Rochester, Minnesota) |
| Trial ID | NCT05854303 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess how stopping opioid use impacts patients suffering from opioid-induced esophageal dysfunction (OIED). It will involve patients enrolled in a Pain Rehabilitation Center who are undergoing opioid cessation, with or without existing esophageal symptoms. The study will compare outcomes between those who cease opioid use and those who do not, providing insights into the relationship between opioid use and esophageal health.
Who should consider this trial
Good fit: Ideal candidates are patients enrolled in the Pain Rehabilitation Center who are undergoing opioid cessation and may have esophageal symptoms.
Not a fit: Patients with previous gastroesophageal surgery, esophageal stricture, or certain other specific conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help improve treatment strategies for patients experiencing esophageal dysfunction related to opioid use.
How similar studies have performed: While there is limited information on similar studies, the approach of evaluating opioid cessation effects on esophageal dysfunction is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- Patients enrolled in the Pain Rehabilitation Center for opioid cessation, with or without esophageal symptoms. Exclusion Criteria: * Inability to provide informed consent. * Patients with previous gastroesophageal surgery or pneumatic dilation. * Esophageal botulinum toxin injection within the prior 12 months. * Esophageal stricture * Achalasia types I and II * Allergy to Lidocaine or other local anesthetics * Subjects on anticoagulation * Bilateral nasal obstruction * Pregnancy or breast feeding
Where this trial is running
Rochester, Minnesota
- Mayo Clinic Minnesota — Rochester, Minnesota, United States (Recruiting)
Study contacts
- Principal investigator: Diana Snyder, MD — Mayo Clinic
- Study coordinator: Mariah Robran
- Email: robran.mariah@mayo.edu
- Phone: 507-266-3595
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.